Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023

BUY
$0.66 - $1.29 $235,519 - $460,332
356,847 New
356,847 $266 Million
Q4 2022

Feb 14, 2023

BUY
$1.1 - $2.45 $396,825 - $883,837
360,750 New
360,750 $447,000
Q3 2022

Nov 14, 2022

BUY
$1.96 - $3.32 $67,896 - $115,008
34,641 Added 10.57%
362,413 $746,000
Q2 2022

Aug 15, 2022

BUY
$2.27 - $4.86 $56,829 - $121,670
25,035 Added 8.27%
327,772 $908,000
Q1 2022

May 11, 2022

BUY
$3.69 - $5.65 $20,342 - $31,148
5,513 Added 1.85%
302,737 $1.32 Million
Q4 2021

Feb 11, 2022

BUY
$5.37 - $7.07 $50,365 - $66,309
9,379 Added 3.26%
297,224 $1.64 Million
Q3 2021

Nov 12, 2021

SELL
$5.54 - $7.51 $476,445 - $645,867
-86,001 Reduced 23.0%
287,845 $1.78 Million
Q2 2021

Aug 11, 2021

SELL
$7.78 - $11.4 $18,197 - $26,664
-2,339 Reduced 0.62%
373,846 $3.18 Million
Q1 2021

May 13, 2021

BUY
$5.12 - $8.48 $863,057 - $1.43 Million
168,566 Added 81.19%
376,185 $2.98 Million
Q4 2020

Feb 09, 2021

BUY
$3.16 - $7.03 $115,861 - $257,754
36,665 Added 21.45%
207,619 $1.21 Million
Q3 2020

Nov 12, 2020

SELL
$3.26 - $4.73 $5,163 - $7,492
-1,584 Reduced 0.92%
170,954 $579,000
Q2 2020

Aug 12, 2020

BUY
$1.58 - $4.63 $17,539 - $51,397
11,101 Added 6.88%
172,538 $797,000
Q1 2020

May 06, 2020

BUY
$1.44 - $3.02 $7,623 - $15,987
5,294 Added 3.39%
161,437 $255,000
Q4 2019

Feb 14, 2020

BUY
$2.25 - $3.07 $41,073 - $56,042
18,255 Added 13.24%
156,143 $427,000
Q3 2019

Nov 07, 2019

BUY
$2.67 - $3.65 $63,532 - $86,851
23,795 Added 20.86%
137,888 $405,000
Q2 2019

Aug 12, 2019

BUY
$2.6 - $4.21 $296,641 - $480,331
114,093 New
114,093 $327,000

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $520M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.